Philip A. Harris

Philip A. Harris

Auto-generated profile, based on publicly available information

Philip A. Harris

Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA 19426, USA

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2017
Verified
Closed access
PHPhilip A. Harris
Philip A. Harris
SBScott B. Berger
Scott B. Berger
JJJae U. Jeong
Jae U. Jeong
RNRakesh Nagilla
Rakesh Nagilla
DBDeepak Bandyopadhyay
Deepak Bandyopadhyay
JBJohn Bertin
John Bertin

15 June 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SBScott B. Berger
Scott B. Berger
VKViera Kasparcova
Viera Kasparcova
SHSandy Hoffman
Sandy Hoffman
BSBarb Swift
Barb Swift
LDLauren Dare
Lauren Dare
PGPeter J. Gough
Peter J. Gough
RIP1 (RIPK1) kinase is a key regulator of TNF-induced NF-κB activation, apoptosis, and necroptosis through its kinase and scaffolding activities. Dissecting the balance of RIP1 kinase activity and scaffolding function in vivo during development and TNF-dependent inflammation has been hampered by the perinatal lethality of RIP1-deficient mice. In this study, we generated RIP1 kinase–dead (Ripk1K45A) mice and showed they are viable and healthy, indicating that the kinase activity of RIP1, but not its scaffolding function, is dispensable for viability and homeostasis. After validating that the Ripk1K45A mice were specifically protected against necroptotic stimuli in vitro and in vivo, we crossed them with SHARPIN-deficient cpdm mice, which develop severe skin and multiorgan inflammation that has been hypothesized to be mediated by TNF-dependent apoptosis and/or necroptosis. Remarkably, crossing Ripk1K45A mice with the cpdm strain protected against all cpdm-related pathology. Together, these data suggest that RIP1 kinase represents an attractive therapeutic target for TNF-driven inflammatory diseases.

12 July 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PHPhilip A. Harris
Philip A. Harris
ABAmogh Boloor
Amogh Boloor
MCMui Cheung
Mui Cheung
RKRakesh Kumar
Rakesh Kumar
RCRenae M. Crosby
Renae M. Crosby
JSJeffrey A. Stafford
Jeffrey A. Stafford

31 October 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YMYu Matsuzawa-Ishimoto
Yu Matsuzawa-Ishimoto
YSYusuke Shono
Yusuke Shono
LGLuis E. Gomez
Luis E. Gomez
VHVanessa M. Hubbard-Lucey
Vanessa M. Hubbard-Lucey
MCMichael Cammer
Michael Cammer
KCKen Cadwell
Ken Cadwell
A variant of the autophagy gene ATG16L1 is associated with Crohn’s disease, an inflammatory bowel disease (IBD), and poor survival in allogeneic hematopoietic stem cell transplant recipients. We demonstrate that ATG16L1 in the intestinal epithelium is essential for preventing loss of Paneth cells and exaggerated cell death in animal models of virally triggered IBD and allogeneic hematopoietic stem cell transplantation. Intestinal organoids lacking ATG16L1 reproduced this loss in Paneth cells and displayed TNFα-mediated necroptosis, a form of programmed necrosis. This cytoprotective function of ATG16L1 was associated with the role of autophagy in promoting mitochondrial homeostasis. Finally, therapeutic blockade of necroptosis through TNFα or RIPK1 inhibition ameliorated disease in the virally triggered IBD model. These findings indicate that, in contrast to tumor cells in which autophagy promotes caspase-independent cell death, ATG16L1 maintains the intestinal barrier by inhibiting necroptosis in the epithelium.

23 February 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PHPhilip A. Harris
Philip A. Harris
BKBryan W. King
Bryan W. King
DBDeepak Bandyopadhyay
Deepak Bandyopadhyay
SBScott B. Berger
Scott B. Berger
NCNino Campobasso
Nino Campobasso
PGPeter J. Gough
Peter J. Gough

1 February 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
HGHongyan Guo
Hongyan Guo
SOShinya Omoto
Shinya Omoto
PHPhilip A. Harris
Philip A. Harris
JFJoshua N. Finger
Joshua N. Finger
JBJohn Bertin
John Bertin
EMEdward S. Mocarski
Edward S. Mocarski